

Anti-diarrheal drug loperamide induces dysbiosis in zebrafish microbiota via bacterial inhibition

Rebecca Stevick, Sébastien Bedu, Nicolas Dray, Jean-Marc Ghigo, David

Pérez-Pascual

► To cite this version:

Rebecca Stevick, Sébastien Bedu, Nicolas Dray, Jean-Marc Ghigo, David Pérez-Pascual. Antidiarrheal drug loperamide induces dysbiosis in zebrafish microbiota via bacterial inhibition. 2023. pasteur-04253857v1

HAL Id: pasteur-04253857 https://pasteur.hal.science/pasteur-04253857v1

Preprint submitted on 23 Oct 2023 (v1), last revised 12 Nov 2024 (v2)

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

1 Anti-diarrheal drug loperamide induces dysbiosis in zebrafish microbiota

- 2 via bacterial inhibition
- 3
- 4 Rebecca J. Stevick¹, Sébastien Bedu², Nicolas Dray², Jean-Marc Ghigo^{1#} and David Pérez-
- 5 Pascual^{1#}
- 6 ¹ Institut Pasteur Université Paris Cité, CNRS UMR 6047, Genetics of Biofilms Laboratory,
- 7 Paris, France
- 8 ² Institut Pasteur Université Paris Cité, CNRS UMR 3738, Zebrafish Neurogenetics Laboratory,
- 9 Paris, France

- 11 **#Co-corresponding Authors:**
- 12 David Pérez-Pascual (<u>dperezpascu@gmail.com</u>)
- 13 Jean-Marc Ghigo (jmghigo@pasteur.fr)
- 14
- 15 Keywords: zebrafish, microbiota, host-microbe system, dysbiosis, loperamide, colonization,
- 16 antibacterial activity

17 Abstract

18 Background

Perturbations of animal-associated microbiomes from chemical stress can affect host physiology and health. While dysbiosis induced by antibiotic treatments and disease are well known, chemical, non-antibiotic drugs have recently been shown to induce changes in microbiome composition, warranting further exploration. Loperamide is an opioid-receptor agonist drug widely prescribed drug for treating acute diarrhea in humans. Loperamide is also used as a tool to study the impact of bowel dysfunction in animal models by inducing constipation, but its effect on host-associated microbiota is poorly characterized.


26 *Results*

We used conventional and gnotobiotic larval zebrafish models to show that in addition to hostspecific effects, loperamide also has anti-bacterial activities that directly induce changes in microbiota diversity. This dysbiosis is due to changes in bacterial colonization, since germ-free zebrafish mono-reconventionalized with bacterial strains sensitive to loperamide are colonized up to 100-fold lower when treated with loperamide. Consistently, the bacterial diversity of gnotobiotic zebrafish colonized by a mix of representative bacterial strains is affected by loperamide treatment.

34 Conclusion

Our results demonstrate that loperamide, in addition to host effects, also induces dysbiosis in a vertebrate model, highlighting that established treatments can have underlooked secondary effects on microbiota structure and function. This study further provides a insights for future studies exploring how common medications directly induce changes in host-associated microbiota.

41 Graphical Abstract



45 Background

46

Animal-associated microbiomes are dynamic communities that play essential roles in the physiology, health, and evolution of their hosts [1]. Numerous studies have explored the impact of different phenomena on microbiota stability, including antibiotic treatments, gut health, or environmental factors, in order to understand the consequences of microbiota perturbations on host functions [2–5]. These perturbations may lead to dysbiosis or a change in microbial community composition and/or function, relative to the steady state, with potential implications for host health [6, 7].

54

55 While the complexity of microbiota in humans and animal models limits functional and 56 mechanistic studies, germ-free and gnotobiotic animal models with controlled, tractable 57 microbiota are widely used to study host-microbiota interactions [8]. Compared to conventional 58 animals with relatively variable microbiota [9], gnotobiotic animals with host-specific bacterial 59 consortia can mimic key phenotypes for mechanistic studies, and are powerful tools to simplify microbiota and increase experimental reproducibility [10]. In particular, zebrafish (Danio 60 61 rerio), which possesses both an innate and adaptative immune system and a mammal-like 62 intestinal epithelium, has emerged as an established gnotobiotic model to study vertebrate host-63 microbiota interactions [11, 12]. Gnotobiotic larval zebrafish can indeed be easily reared to 64 study simplified host-microbial systems in the context of developmental biology, immunology, 65 and disease [13, 14].

66

67 Loperamide is a prevalent medication for treating diarrhea in humans and animals that acts on 68 μ -opioid receptors in the large intestine, decreasing intestinal peristaltic activity and increasing 69 the absorption of fluids [15-18]. Loperamide is also used to study bowel dysfunction and 70 constipation in animal models, including rats, mice, and zebrafish, generating a relevant model 71 of irritable bowel syndrome or opioid-induced bowel dysfunction disorder [19-21]. In 72 zebrafish, loperamide treatment was shown to cause a significant decrease in intestinal 73 peristaltic frequency that can be restored by the presence of specific bacteria or acetylcholine 74 [21, 22].

75

76 Despite its pervasive use in humans and animal models, the potential effects of loperamide on 77 host-associated microbiota *in vitro* and *in vivo* are poorly characterized. It has been suggested 78 that slow transit time and constipation induced by loperamide could be responsible for changes

79 in bacterial composition and decreased diversity observed in rats and mice [23–26]. Although 80 publications using loperamide to investigate host-associated microbiota establish the link 81 between constipation and microbial dysbiosis, recent studies have identified loperamide 82 hydrochloride and its derivatives as molecules displaying bactericidal activity [27–29]. Hence 83 the extent of microbial dysbiosis directly caused by this compound versus its impact on the 84 alteration of host function are poorly understood and ignored in animal models. 85

In this study, we used conventional and gnotobiotic larval zebrafish to reproduce in vivo 86 87 loperamide-induced dysbiosis based on in vitro bacterial sensitivity to loperamide. We found 88 that loperamide leads to recoverable dysbiosis in conventional larval zebrafish according to 89 strain-specific inhibition or promotion of bacteria. Our results demonstrate how a relevant 90 chemical perturbation induces dysbiosis in a vertebrate microbiome model. These findings 91 should be considered in the context of secondary effects of established treatments, assumed 92 mode of action in animal models, and microbiota community recovery.

93 Methods

94

95 General zebrafish husbandry

Wild-type AB/AB zebrafish (Danio rerio) fertilized eggs at 0 days post fertilization (dpf) were 96 97 obtained from the Zorgl'hub platform at Institut Pasteur. All procedures were performed at 98 28°C under a laminar microbiological hood with single-use disposable plastic ware according 99 to European Union guidelines for handling of laboratory animals and were approved by the 100 relevant institutional Animal Health and Care Committees. Eggs were kept in 25 cm³ vented 101 flasks (Corning 430639) with 20 mL of autoclaved mineral water (Volvic) until 4 dpf (30 - 33 102 eggs/flask) and transferred to new flasks after hatching at 4 dpf (10 - 15 fish/flask). At 6 dpf, 103 each fish was transferred to an individual well of a 24-well plate (TPP 92024) in 2 mL of 104 autoclaved mineral water and maintained until the end of the experiment (11 dpf). Conventional 105 zebrafish embryos were transferred to flasks at 1 dpf and maintained as described. At the end 106 of the experiment, zebrafish were euthanized with an overdose of tricaine (MS-222, Sigma-107 Aldrich E10521) at 0.3 mg/mL for 10 minutes.

108

109 Fish were fed with sterile *Tetrahymena thermophila* every 48 hours starting at 4 dpf. Germ-free 110 T. thermophila stocks were kept in 15 mL of PPYE broth (0.25% protease peptone BD Bacto 111 #211684, 0.25% yeast extract BD Bacto #212750) supplemented with penicillin G (10 unit/mL) 112 and streptomycin (10 μ g/mL) at 28°C. Every week, a new stock was inoculated with 100 μ L of 113 the previous stock and tested for sterility on LB, TYES, and YPD agar media plates. To prepare 114 food for the zebrafish, T. thermophila was inoculated at a 1:50 ratio from the stock into 20 mL 115 MYE broth (1% milk powder, 1% yeast extract) and grown for 2 days. On feeding day, the T. 116 thermophila was transferred to a 50 mL Falcon tube and washed 3 times (4400 rpm, 3 min at 117 25 °C) with sterile mineral water. Resuspended T. thermophila was added to the fish in culture flasks (500 µL in 20 mL) or 24-well plates (50 µL in 2 mL). 118

119

120 Germ-free zebrafish sterilization

The zebrafish embryos were sterilized as previously described with the following modifications [13, 30]. Recently fertilized zebrafish eggs (0 dpf) were bleached (0.000005 % final v/v) for 5 minutes, then washed 2 times in sterile mineral water. Eggs were then maintained in 50 mL Falcon tubes (100 eggs/tube) overnight in 35 mL of sterile mineral water supplemented with 0.4 μ g/mL methylene blue solution (Sigma Aldrich 50484). At 1 dpf, the volume of each tube was adjusted to 50 mL and the eggs were treated with an antibiotic cocktail for 2 hours with

127 gentle agitation at 10 rev/min: penicillin G: streptomycin at 100 µg/mL (GIBCO 15140148), 128 kanamycin sulfate at 400 µg/mL (PAN BIOTECH P06-04010P) and amphotericin B solution 129 at 250 µg/mL (Sigma-Aldrich A2942). Then, the eggs were washed 3 times with sterile mineral 130 water and resuspended in 50 mL water. The eggs were bleached (0.000005 % final v/v) for 15 131 minutes with inversion every 3 minutes, then washed 3 times in sterile mineral water and 132 resuspended in 50 mL water. Finally, the eggs were treated with 1 % Romeoid solution (COFA, 133 France) for 10 minutes, then washed 3 times in sterile mineral water. Eggs were then transferred 134 to 25 cm³ vented flasks and maintained as described above.

135

Sterility was confirmed at 3 dpf by spotting 50 µL of water from each flask on LB, TYES and YPD agar plates and incubated at 28 °C under aerobic conditions for at least 3 days. In addition, monthly checks of bacterial contamination were done by PCR amplification of water samples with 16S rRNA gene primers as described below in the characterization section. Contaminated flasks were immediately removed from the experiment and not included in the results.

141

142 Germ-free zebrafish re-conventionalization

143 Germ-free zebrafish larvae were re-conventionalized at 4 dpf, as follows. Overnight cultures of a single bacterial colony in 5 mL of liquid media were washed twice with sterile Volvic water 144 145 and normalized to OD-0.1 in water. For mono-reconventionalization, 200 µL of bacterial 146 suspension was added into flasks of germ-free zebrafish in 20 mL of Volvic water at a final 147 concentration of 5 x 10^5 CFU/mL. For mix-reconventionalization, 200 μ L of each strain was added per flask at a final concentration of 5 x 10^5 CFU/mL per strain. Water samples were 148 149 plated in serial dilutions to confirm final bacterial concentration and sterility. Re-150 conventionalization was performed for 48 hours until fish were transferred to sterile water in 151 24-well plates.

152

153 Zebrafish loperamide treatment

Loperamide hydrochloride (Sigma-Aldrich 34014) was dissolved in pure dimethyl sulfoxide (DMSO, Sigma-Aldrich D8418) at a stock concentration of 100 mg/mL. Larval zebrafish were treated at 5 dpf with loperamide at a final concentration of 10 mg/L in 20 mL vented flasks for 24 hours, which has been previously shown to significantly reduce peristaltic movement in larval zebrafish at 4 - 6 dpf [21]. Sterile DMSO added at a final concentration of 1:10000 was used as the control. After 24 hours of treatment, all 6 dpf fish were transferred to water and maintained until sampling.

161

162 Conventional zebrafish sampling and DNA extraction

163 Zebrafish larvae were sampled at each of 3 timepoints (6 dpf, 7 dpf, 11 dpf) with 3 treatment 164 conditions (control water, DMSO 1:10000, Loperamide 10 mg/L) as follows. At each 165 timepoint, 5 larval fish per condition (15 total) were washed twice by transfers to clean, sterile 166 water to remove environmental and residual bacteria. Each fish was then added to a sterile 2-167 mL microcentrifuge tube in 200 μ L of water and euthanized with tricaine at 0.3 mg/mL. All 168 liquid was removed from the tissue, then the samples (45 total) were immediately frozen at -169 80°C and stored until DNA extraction.

170

171 DNA extraction was performed from single larval zebrafish using the DNeasy Blood & Tissue 172 kit (Qiagen 69504) with modifications as follows. Tissue samples were thawed at room 173 temperature, then 380 µL Buffer ATL and 20 µL proteinase K were added directly to each individual larva in a 2 mL tube. Samples were vortexed for 15 seconds, then incubated 174 175 overnight (15-18 hours) at 56°C and 300 rpm until fully lysed. After lysis, 4 µL of RNAse A 176 solution was added and the samples were incubated for 5 minutes at room temperature to 177 remove residual RNA. Next, 400 µL Buffer AL and 400 µL 100 % ethanol were added and 178 mixed by vortexing before loading the lysate onto the DNeasy mini spin column in 2 x 600 μ L 179 loads. DNA purification and cleanup proceeded according to the manufacturer's 180 recommendations with a final elution volume of 50 µL in Buffer AE. Purified DNA was 181 quantified using the Qubit HS DNA fluorometer kit (ThermoFisher Q32851) and purity was 182 assessed with the Nanodrop spectrophotometer (ThermoFisher). DNA yields per single fish 183 sample ranged from 10-15 ng/ μ L in 50 μ L with purity ratios >1.8. Negative controls for the 184 extraction kit were prepared alongside zebrafish samples, but with no tissue input.

185

186 Conventional fish 16S rRNA gene amplicon sequencing and analysis

187 16S rRNA gene amplicons of the V6 region for the 45 conventional zebrafish samples, 2 mock 188 community samples (Zymo Research DNA standard I D6305), 2 negative DNA extraction 189 samples, and blank PCR control were prepared using 967F/1064R primers. The DNA extraction 190 negative control samples were pooled and concentrated prior to PCR to obtain enough product 191 for sequencing. A two-step PCR reaction using 200 ng of zebrafish DNA was performed in 192 duplicate 50 µL reactions as previously described [31, 32]. Each first step reaction included 25 193 μL 2X Phusion Mastermix (Thermo Scientific F531S), 1.5 μL of 10 μM F/R primer mix (967F: 194 CTAACCGANGAACCTYACC, CNACGCGAAGAACCTTANC,

CAACGCGMARAACCTTACC, ATACGCGARGAACCTTACC (equimolar mix) / 1064R: 195 196 CGACRRCCATGCANCACCT), 13 - 20 μ L template DNA (200 ng), and 3.5 - 10.5 μ L 197 nuclease-free water (up to 50 µL). PCR amplification (step 1) conditions were denaturing at 198 98°C for 3 min followed by 30 cycles of denaturation at 98°C for 10 s, primer annealing at 199 56°C for 30 s, and extension at 72°C for 20 s, then a final extension at 72°C for 20 s. Negative 200 controls for the PCR reagents were prepared alongside zebrafish DNA samples, but with 201 additional nuclease-free water input. PCR products were assed for concentration (Qubit DNA 202 HS reagents) and expected size using agarose gel electrophoresis. A second PCR step was 203 performed to attach sequencing barcodes and adaptors according to Illumina protocols. The 204 PCR products were analyzed with 250 bp paired-end sequencing to obtain overlapping reads 205 on an Illumina MiSeq at the Institut Pasteur Biomics platform.

206

207 The resulting 16S rRNA gene amplicon sequences were demultiplexed and quality filtered 208 using DADA2 (v1.6.0) implemented in QIIME2 (v2020.11.1) with additional parameters --p-209 trunc-len-r 80 --p-trunc-len-f 80 --p-trim-left-r 19 --p-trim-left-f 19 to determine amplicon 210 sequence variants (ASVs) [33, 34]. All ASVs were summarized with the QIIME2 pipeline 211 (v2020.11.1) and classified directly using the SILVA database (99 % similarity, release #134) 212 [35, 36]. Processed ASV and associated taxonomy data was exported as a count matrix for 213 analysis in R (v4.1.3). The positive and negative controls were checked to ensure sequencing quality and expected relative abundances. Non-bacterial and chloroplast sequences were then 214 215 removed, and the data was normalized by percentage to the total ASVs in each sample for 216 further dissimilarity metric analysis.

217

218 All descriptive and statistical analyses were performed in the R statistical computing 219 environment with the *tidvverse* v1.3.1, *vegan* v2.5.7 and *phyloseq* v1.38.0 packages [37–39]. 220 Rarefaction curves and sequencing coverage estimates were generated using the rarecurve() 221 commands with sample=[number of reads in smallest sample] in vegan v2.5.7 [40]. Non-metric 222 dimensional analysis (NMDS) was used to determine the influence of timepoint or loperamide 223 treatment on the ASV-level composition. The Bray-Curtis dissimilarity metric was calculated 224 with k = 2 for max 50 iterations and 95 % confidence intervals (standard deviation) were 225 plotted. Statistical testing of the beta-diversity was done using the PERMANOVA adonis2 test implemented in *vegan* (method = "bray", k = 2) [41, 42]. Within-condition variability was 226 227 calculated using the command vegdist(method = "bray", k = 2) and the matrix was simplified 228 to include samples compared within each timepoint.

229

230 Significant differences in genera between DMSO (reference) and loperamide-treated (test) at 231 each timepoint were calculated using *limma* implemented in the *microbiomeMarker* v1.1.2 232 package using the following conditions: norm = "RLE", pvalue cutoff = 0.05, taxa rank = 233 "Genus", p adjust = "fdr" [43–45]. Simpson's diversity values were calculated for each sample 234 at the ASV level using the vegan package and analyzed using the non-parametric Kruskal-235 Wallis rank sum test in R. Additional visualizations were computed using the ComplexHeatmap 236 v2.10.0 and UpSetR v1.4.0 packages [46, 47]. All processed sequencing files, bash scripts, 237 QIIME2 artifacts, and Rmd scripts to reproduce the figures in the manuscript are available on 238 Zenodo [48].

239

240 Measurement of zebrafish growth and development

241 In order to determine the effect of loperamide growth on larval fish growth and development, 9-10 fish were sampled at each timepoint (6, 7, 11 dpf) for each condition (control water, 242 243 DMSO, loperamide) = 85 fish total. After euthanasia, the samples were fixed in 1 % 244 paraformaldehyde (PFA) and stored at 4°C. After fixation, the samples were rinsed 3 times with 245 PBS then placed into individual wells in a plate. Microscopy images were taken with a Leica 246 M80 10X with a Leica IC80 HD camera. Four images were captured per sample: whole at 2.5X, 247 caudal at 5X, lateral at 5X and head at 5X for a total of 337 images for 85 samples. Relevant 248 measurements of each fish sample were performed using ImageJ [49]. Four measurements in 249 millimeters were taken per fish: eye diameter, rump-anus length, standard length, and tail width 250 according to methods previously described [50–52].

251

252 Bacterial strains and growth conditions

Bacterial strains are listed in Supplementary Table S1. Zebrafish-associated strains were grown
in Tryptone Yeast Extract Salts (TYES) or Miller's Lysogeny Broth (LB) (Corning) and
incubated at 28°C with rotation. Cultures on solid media were on LB or TYES with 1.5 % agar.
Bacteria were always streaked from glycerol stocks on LB- or TYES-agar before inoculation
with a single colony in liquid cultures. All media and chemicals were purchased from SigmaAldrich.

259

260 Isolation and 16S characterization of bacteria from conventional zebrafish

Five of the zebrafish-associated strains were previously isolated and characterized from the zebrafish environment [53]. The following strains were isolated and identified in the same way

263 in this study: S2, S4, S8, S9. Zebrafish lysates and tank water were serially diluted and plated 264 on R2A, TYES, and LB agar and incubated at 28°C for up to 3 days. Each colony morphotype 265 per media was catalogued and re-streaked on the same agar. The morphotype identification was 266 done as previously described [53, 54]. Individual colonies were picked for each morphotype 267 from each agar plates, vortexed in 200 µl DNA-free water and boiled for 10 min at 90°C. Five 268 µl of this bacterial suspension was used as template for colony PCR to amplify the 16S rRNA 269 gene with the universal primer pair 27f and 1492R. 16S rRNA gene PCR products were verified 270 on 1% agarose gels, purified with the QIAquick PCR purification kit (Qiagen) and two PCR 271 products for each morphotype were sent for sequencing (Eurofins, Ebersberg, Germany). 272 Individual 16S rRNA- gene sequences were compared with those available in the EzBioCloud 273 database. Species-level identification was performed based on the 16S rRNA gene sequence 274 similarity was >99%. The zebrafish-associated strains used in this study (Table S1) were chosen 275 from this catalogue based on their sensitivity to loperamide and match with significant changes 276 in the conventional 16S rRNA gene amplicon data.

277

278 Bacterial growth curves and survival assays

279 Overnight cultures of a single bacterial colony in 5 mL of liquid media were measured and 280 normalized to OD-0.5. Liquid media supplemented with 10 mg/L loperamide in DMSO or 281 1:10000 DMSO or control was added to a TPP flat-bottom polystyrene 96-well plate. Bacterial 282 cultures were added to each condition in triplicate at a final starting concentration of OD-0.05 283 in 100 µL. Negative control wells were included for each media and condition. A plastic adhesive film (adhesive sealing sheet, Thermo Scientific, AB0558) was used to seal the wells, 284 285 and the plates were then incubated in a TECAN Infinite M200 Pro spectrophotometer for 20 286 hours at 28°C. OD600 was measured every 30 minutes, after a 30-second orbital shaking of 2 287 mm amplitude.

288

289 Bacterial survival in water was tested using the *in vivo* re-conventionalization conditions 290 described above. Overnight cultures of a single bacterial colony in 5 mL of liquid media were 291 washed twice with autoclaved Volvic water, measured and normalized to OD-0.1 in water. 292 Bacteria were inoculated at a final concentration of 5 x 10⁵ CFU/mL into 10 mL of Volvic water 293 supplemented with loperamide in DMSO at 10 mg/L or 1:10000 DMSO or control. Viable 294 colony forming units (CFUs) were counted from each flask at 0, 6, 24, 48, and 72 hours as 295 follows. Three x 200 μ L aliquots were sampled and dilutions were made, then 10 μ L drops 296 were plated on LB or TYES and grown at 28°C for 2 days. CFUs were then counted for each

297 strain and CFUs/mL were calculated by $1000 \,\mu$ L/mL / $10 \,\mu$ L plated * dilution factor * (average 298 of replicate CFUs per strain). Survival of each strain was repeated at least two independent 299 times.

300

301 Quantification of gnotobiotic zebrafish bacterial load by CFU counts

302 Zebrafish were sampled at each of 3 timepoints (6 dpf, 7 dpf, 11 dpf) with 3 treatment 303 conditions (control water, DMSO 1:10000, Loperamide 10 mg/L). At each timepoint, 3-4 larval 304 fish per condition were washed twice by 2 transfers to clean, sterile water in petri dishes to 305 remove environmental and residual bacteria. The larvae were then euthanized with tricaine at 306 0.3 mg/mL and added in 500 µL of sterile water to 2 mL tubes containing 1.4 mm ceramic 307 beads (Fischer Scientific 15555799). Fish were homogenized for 2 x 45 seconds at 6000 rpm 308 using a 24 Touch Homogenizer (Bertin Instruments). These homogenization conditions are 309 sufficient to lyse zebrafish tissue, but not harmful to the bacteria. The lysate was then diluted 310 from 10-100-fold. For the mono-reconventionalized fish, 10 µL drops were plated in triplicate 311 for each dilution on media. After 2 days of incubation at 28°C, CFUs were counted and CFUs 312 per fish were calculated by 500 µL lysate / 10 µL plated * dilution factor * average of replicate 313 CFUs. For the mix-reconventionalized fish, 3 x 100 µL from each dilution was spread on media 314 using sterile glass beads to differentiate the colonies. After 2 days of incubation at 28°C, CFUs 315 were counted for each strain and CFUs per strain per fish were calculated by 500 µL lysate / 100 µL plated * dilution factor * (average of replicate CFUs per strain). 316

317

318 Statistical Analyses

319 All plotting and statistical analyses were performed in the R statistical computing environment 320 (4.1.3) using RStudio (v.2022.02.1) with the *tidyverse* v1.3.1, ggpubr v0.4.0, ggtext v0.1.1 and 321 patchwork v1.1.1 packages [39, 55-57]. Non-parametric global Kruskal-Wallis tests and 322 subsequent Wilcoxon pairwise tests were performed to compare loperamide-treated condition 323 to the DMSO control using compare means() or stat compare means() when p<0.05 is 324 significant. For the comparison of zebrafish colonization and water survival, mean CFUs/mL 325 or CFUs/fish of each strain S1 – S10 were calculated for control conditions at 48 h or T0, 326 respectively. The colonization efficiency for each strain was calculated by Colonization 327 *efficiency* = *mean CFUs per Fish / mean Water CFUs per mL* * 100. The correlation between the variables was fit with geom smooth(method = "lm") and the fit was indicated with 328 329 correlations using stat cor() and stat regline equation(). Hypothetical bacterial composition 330 comparison of mono-reconventionalized fish was calculated by the mean CFUs per fish per

strain / the sum of mean CFUs per fish of S1, S3, S5, S6, S7. Bacterial composition comparison of mix-reconventionalized fish was calculated by the mean CFUs of each strain / the total CFUs of all strains in each fish. Simpson's diversity values were calculated for each mixreconventionalized fish based on percent abundance per strain using the *vegan* package and analyzed using the non-parametric Kruskal–Wallis rank sum test in R. All raw data and Rmd scripts to reproduce the figures and statistical tests in the manuscript are available on Zenodo [48].

- 338
- 339 **Results**
- 340

341 Loperamide treatment induces recoverable dysbiosis in conventional larval zebrafish 342 microbiota

Using the experimental procedure described in Figure 1, we determined the impact of 343 344 loperamide treatment on conventional larval zebrafish microbiota using 16S rRNA gene 345 amplicons sequenced from whole fish samples after 24 hours of treatment (T0), 24 hours of 346 recovery (T1), and 5 days of recovery (T5). A total of 2,161,882 quality-controlled, bacterial 347 16S rRNA gene amplicon sequences were analyzed from 45 larval zebrafish samples (Fig. 348 S1A). Sequence variant analysis using QIIME2 and taxonomic classification resulted in the 349 detection of 1,186 bacterial genera across 39 phyla, to sufficiently cover the estimated high 350 diversity in the samples (Fig. S1B). Blank negative control samples were analyzed to confirm 351 the absence of contamination relative to the zebrafish samples and a sequenced mock 352 community yielded the expected sequencing proportions (Fig. S2). Proteobacteria was the 353 dominant phylum in the larval zebrafish microbiota comprising $75 \pm 17\%$ of the samples, 354 followed by Bacteroidota (9.6 \pm 9.2%) and Firmicutes (5.0 \pm 13%) (Fig. S3; values averaged 355 across all samples). The largest group of 100 shared genera was common to all DMSO and 356 loperamide samples, regardless of timepoint or treatment (Fig. S4B; black bar).




Figure 1. Experimental scheme of the larval zebrafish assays and sample collection. Conventional, mono-conventionalized, or Mix5-conventionalized larval zebrafish were exposed at 5 dpf to water (control), DMSO (control) or 10 mg/L loperamide hydrochloride (treated) for 24 hours, then transferred to water at 6 dpf. Samples were collected at 6 dpf, 7 dpf, and 11 dpf (T0, T1, T5) to measure fish growth and quantify bacterial community composition in all conditions (dpf = days post fertilization; CFUs = colony forming units).

358

359

360 Differences in the conventional zebrafish bacterial community composition were observed 361 between the timepoints and treatment (Figs. 2, S3, S4, and S5). At T0 and T1, the beta-diversity of loperamide-treated fish microbiota was significantly different from the DMSO control (Figs. 362 2A, S5BC; adonis2 PERMANOVA $R^2 = 0.43$, 0.51; p < 0.01). However, after 5 days of 363 recovery (T5), the DMSO and loperamide-treated fish microbiota composition was not 364 365 significantly different, indicating a recovery of microbiota composition once the treatment ended (Fig. 2A, S5D; adonis2 PERMANOVA $R^2 = 0.22$; p > 0.05). This recoverable dysbiosis 366 367 in microbiota composition induced by loperamide treatment was driven by a decrease in genus 368 Ensifer and an increase in genus Aeromonas at T0 (Figs. 2B, S4A). At T1, there were major significant differences, affecting 37 different taxonomic groups, 6 of them with >1% 369 370 abundance: a 4-log decrease in *Acidovorax* and significant enrichment of *Comamonadaceae*, 371 Acinetobacter, Flavobacterium, Oxalobacteraceae, and Rheinheimera taxa (Fig. 2B). After 5 372 days of recovery at T5, there were no significantly different genera that were >1% abundant in 373 the conventional zebrafish (Fig. 2B). Loperamide treatment also resulted in significantly 374 decreased within-group beta-diversity compared to the DMSO control at T0 and T1, but not T5 375 (Fig. 2C). Despite the differences in bacterial composition and treatment regimen, growth and 376 development of conventional zebrafish at all three timepoints was not affected by loperamide 377 treatment (Fig. S6).




Figure 2. Loperamide affects conventional zebrafish microbiota as measured by 16S rRNA gene amplicons. (A) NMDS plot calculated using Bray-Curtis beta-diversity (k = 2) of percent normalized ASVs from 16S rRNA gene amplicons. Ellipse lines show the 95 % confidence interval (standard deviation). Stress = 0.136; adonis2 PERMANOVA R² = 0.104; $p = 0.029^*$. Only DMSO and loperamide-treated samples are shown. (B) Significant differentially abundant genera in loperamide-treated fish, compared to DMSO controls at each timepoint calculated using Limma (one-against-one) with conditions: relative log expression (RLE) normalized, effect log fold change >2, Benjamini & Hochberg adjusted p-value < 0.05 (n = 5 per condition). Genera that occur at mean percent abundance >1% are outlined in black and bold. (C) Beta-dispersion or within-condition dissimilarity index calculated using Bray-Curtis beta-diversity (n = 20). **** p<0.001 for Loperamide treatment, compared to DMSO. Wilcoxon test.

379

380

381 Members of the conventional zebrafish community are inhibited or promoted by loperamide 382 in vitro

Based on the changes observed in the conventional zebrafish bacterial community, 9 strains isolated from the zebrafish environment (conventional larvae or rearing water) and a *Flavobacterium* spp. were tested for their sensitivity to loperamide *in vitro* (Table S1). When 386 grown in rich media in the presence of loperamide, the growth of 8/10 strains was significantly 387 affected, while S2 Variovorax gossypii and S3 Pseudomonas nitroreducens were not affected 388 (Fig. S7). One strain (S1 Pseudomonas mosselii) showed increased growth rate and carrying 389 capacity in the presence of loperamide, compared to DMSO control. All other affected strains 390 (7/10) showed no growth, delayed growth, slower growth rates or reduced carrying capacity 391 when grown in media supplemented with loperamide (Fig. S7). In addition to growth, survival 392 in water according to *in vivo* conditions was tested for the 10 strains by counting daily CFUs 393 for three days of incubation. Survival of 6 out of 10 strains was not significantly affected by 394 loperamide in these conditions: S1, S4, S5, S6, S9, and S10 (Fig. 3). Three strains (S2, S3, S8) 395 showed increased survival in the presence of loperamide, while S7 Aeromonas veronii was the 396 only strain with significantly inhibited survival at 24h.






Figure 3. *In vitro* survival in water of zebrafish-associated bacterial strains is affected by loperamide. Survival in water for 72 hours after inoculation at 10^6 CFUs/mL (mean \pm standard deviation per condition is shown, n = 6-12: 2-4 independent assays of 3 biological replicates). * p<0.05 for loperamide treatment, compared to DMSO. Wilcoxon test. Note log scale on y-axis.

398 399

400 Individual bacterial colonization of mono-reconventionalized larval zebrafish is strain-

401 specific and affected by loperamide

402 In order to test the zebrafish colonization capacity of bacteria and the loperamide effects in

403 vivo, 10 bacterial strains were individually added to reconventionalize GF fish and then sampled

404 at T0, T1, and T5 for whole fish CFU counts. All bacterial strains colonized the zebrafish in

405 control conditions at 6 dpf after 2 days of re-conventionalization at 10³ to 10⁶ CFUs per larvae 406 (Fig. 4A). S4 Achromobacter marplatensis had the highest bacterial colonization capacity at a 407 mean of 2.2 x 10⁵ CFU/fish, while the bacterial load of larvae reconventionalized with non-408 autochthonous S10 Flavobacterium johnsoniae was only 4.6 x 10³ CFU/fish. Overall bacterial 409 colonization of the zebrafish was on average 10- to 100-fold lower than the number of CFUs 410 per mL in the water at this time with colonization efficiencies of 0.7 - 52 % (Fig. S8A). Strain 411 S7 A. veronii displayed the highest colonization efficiency with a mean of 1.1 x 10⁵ CFUs/mL in the water, compared to 5.9×10^4 CFUs per fish (efficiency = 52.9 %). Conversely, strains 412 S8, S5, and S2 had colonization efficiencies of $\sim 1\%$ with $\sim 10^6$ CFUs/mL in the water, compared 413 414 to $\sim 10^4$ CFUs per fish (Fig. S8A). Despite these large strain-specific differences in colonization efficiency, overall bacterial colonization per fish correlated with number of bacteria in the water 415 at the time of sampling (Fig. S8B; $R^2 = 0.69$, $p = 0.03^*$). 416

417

418 The addition of loperamide led to a reduction or increase in larval zebrafish bacterial load for 419 half of the assayed strains. Five strains were not significantly affected by loperamide in mono-420 reconventionalized zebrafish: S2, S3, S4, S5, and S6. Colonization of larvae exposed to S1 P. 421 mosselii or S10 F. johnsoniae was significantly reduced in the presence of loperamide at T0 422 and T1, but recovered to match DMSO-level colonization by T5 (Fig. 4B; p < 0.05). S7 A. 423 veronii and S9 Ochrobactrum tritici bacterial load was reduced at all timepoints with 424 loperamide treatment. One strain (S8 *Rhizobium* sp.) showed higher colonization only at T5 425 after loperamide treatment (Fig. 4B; p < 0.05). These strain-specific colonization changes due 426 to loperamide confirm inhibition or promotion of bacteria in vivo, in addition to the host-427 exclusive effects of the molecule. A summary of how loperamide affects in vitro growth and survival, and *in vivo* mono-colonization of all strains is detailed in Table 1. 428




Figure 4. Loperamide can increase or reduce mono-reconventionalized zebrafish colonization. CFUs per fish of mono-reconventionalized fish in (A) control conditions at T0 (6 dpf) ordered by colonization capacity and (B) after exposure to loperamide at 3 timepoints (n = 4 fish). Each point represents a single zebrafish (mean of 3 technical replicates). * p<0.05 for loperamide treatment, compared to DMSO. Wilcoxon test. Note log scale for y-axis.

430

Table 1. Summary of *in vitro* effects of loperamide on zebrafish strains. Significant changes in growth in media, survival in water, and *in vivo* zebrafish colonization for loperamide-treated, compared to DMSO control.

Strain	Growth in media	Survival in water	Zebrafish mono colonization
S1. Pseudomonas mossellii	Promoted	No effect	Reduced at T0 and T1, then recovery
S2. Variovorax gossypii	No effect	Increased from 6 hours	No effect
S3. Pseudomonas nitroreducens	No effect	Increased from 24 hours	No effect
S4. Achromobacter marplatensis	Reduced	No effect	No effect
85. Stenotrophomas maltophilia	Reduced	No effect	No effect
S6. Aeromonas caviae	Inhibited	No effect	No effect
S7. Aeromonas veronii	Inhibited	Decreased at 24 hours	Reduced at T0 and T5

S8. <i>Rhizobium</i> sp.	Inhibited	Increased from 24 hours	Increased at T5
S9. Ochrobactrum tritici	Inhibited	No effect	Reduced at T0
S10. Flavobacterium johnsoniae	Inhibited	No effect	Reduced at T0 and T1, then recovery

431

432 Loperamide treatment induces expected dysbiosis in mix-reconventionalized gnotobiotic
433 larval zebrafish

434 In order to evaluate how loperamide affects a multi-species bacterial community in vivo, germ-435 free zebrafish were reconventionalized with an equal mix of strains S1, S3, S5, S6, and S7. 436 These strains were selected according to their varying sensitivities to loperamide in vitro and 437 *in vivo*. Loperamide treatment did not significantly impact the total number of CFUs per mix-438 reconventionalized fish (Fig. 5A). However, the addition of loperamide induced an increase in 439 S7 A. veronii and a decrease in S6 A. caviae at T0, relative to the DMSO control (Fig. 5B). Meanwhile, S3, S5, and S6 increased in loperamide-treated samples at T1. Finally, at T5 after 440 5 days of recovery, S5 S maltophila and S7 A. veronii were the most abundant strains. (Fig. 441 442 5B). These changes in the proportion of each strain per fish reflect in vitro sensitivity to 443 loperamide and changes measured in conventional fish during loperamide treatment. 444




Figure 5. Loperamide affects mix-reconventionalized gnotobiotic zebrafish bacterial load and composition. (A) Total CFUs per fish of mix-reconventionalized fish after exposure to loperamide at 3 timepoints (n = 3-4 fish). Each point represents a single zebrafish (mean of 3 technical replicates). No significant changes were found for loperamide treatment,

compared to DMSO. Wilcoxon test. Note log scale for CFUs. (**B**) Percent abundance of each strain per mix-reconventionalized fish. Each bar is an individual fish sample.

445 446

447 Differences strain-specific colonization efficiency in zebrafish individually in 448 reconventionalized with these 5 strains may have contributed to loperamide-independent effects 449 on the mix-reconventionalized bacterial colonization (Fig. S8). We compared the mix-450 reconventionalized bacterial composition with the sum of mono-reconventionalized bacterial 451 abundances for S1, S3, S5, S6, and S7 (Fig. S9). This comparison of the mono means to the 452 mix showed that the composition of the mix-reconventionalized fish was different from the sum 453 of the mono-conventionalized fish in all conditions (Fig. S9AB). Therefore, inter-bacterial 454 competition in the mix-reconventionalized fish also contributed to changes in community 455 composition, in addition to host selection and bacterial inhibition by loperamide. Comparison 456 of the CFUs per strain in mono-reconventionalized fish to mix-reconventionalized fish also 457 showed increased colonization for each strain in mono- than when part of a mix, regardless of 458 timepoint or treatment and despite the increased number of bacteria added (Fig. S9CD). Even 459 in control conditions, each strain colonized 10-10000 times higher when added alone than when 460 added as part of a mix (Fig. S9CD).

461

462 Further comparison of the bacterial composition in conventional and gnotobiotic zebrafish focused on changes in alpha-diversity after loperamide treatment and during recovery. 463 464 Loperamide-treated conventional fish alpha-diversity measured by Simpson's Index 465 significantly decreased after 24 hours of loperamide treatment (T0; p<0.05), then increased 466 after 24 hours of recovery (T1) and stayed similar to control diversity at T5 days post-treatment (Fig. 6A). This decrease in diversity was confirmed by the lower number of ASVs (richness) 467 468 detected in the loperamide-treated samples at T0 (Fig. S1B, first panel). Similarly, the alpha-469 diversity of loperamide-treated mix-reconventionalized gnotobiotic zebrafish decreased at T0, 470 significantly increased at T1 (p<0.05), and recovered to match the control at T5 (Fig. 6B). These 471 results show that in both natural and synthetic zebrafish bacterial communities, loperamide 472 induced a significant, but recoverable, dysbiosis and associated loss in diversity.

473




Figure 6. Alpha-diversity of conventional and gnotobiotic zebrafish decreases but recovers after loperamide treatment. Simpson's index of diversity calculated at each timepoint for control water, DMSO, and loperamide-treated samples for (A) 16S rRNA gene amplicon data at the ASV level in conventional fish (n = 5 fish) and (B) CFUs per strain in mix-reconventionalized fish (n = 3-4 fish). Each point represents a single zebrafish with boxplots shown per condition. * p<0.05 for loperamide treatment, compared to DMSO. Wilcoxon test.

476 **Discussion**

477

478 Understanding the impact of non-antibiotic drugs on host-associated microbiota is critical for 479 sustaining health in humans as well as animal models. In this study, we evaluated the effects of 480 loperamide, a widely prescribed anti-diarrheal compound also used as a tool to study the impact 481 of bowel dysfunctions in animal models. Using conventional and gnotobiotic zebrafish, we 482 showed that loperamide directly induced significant but recoverable dysbiosis by broad-range 483 inhibition. The effects of loperamide on zebrafish-associated bacteria characterized by growth, 484 survival, and colonization capacity were strain-specific and changed in the presence of other 485 bacteria or the zebrafish host.

486

487 Loperamide-induced decreases in microbiota alpha-diversity and beta-dispersion immediately 488 after loperamide treatment. These changes were not permanent and initial alpha-diversity 489 recovered within 24 hours after loperamide exposition, and within 5 days for beta-diversity. 490 These results were consistent with a previous study in mice, in which loperamide was used to 491 increase gastrointestinal transit time, but also led to alterations in the gut microbial community 492 that were reversible after treatment interruption [58]. This dysbiosis was presumed to result 493 from a reduction of peristaltic movement, but our results suggest that it could also be explained 494 by the loperamide bactericidal activity [27, 28].

495

496 We found that the effects of loperamide treatment on zebrafish microbiota composition 497 depended on a strain's survival in water and colonization capacity. In conventional zebrafish, 498 loperamide induced a significant increase in the Aeromonas genus at T0, but not at T1 or T5. 499 In mono-reconventionalized fish, S6 A. caviae was not affected by loperamide, but S7 A. 500 veronii showed impaired colonization despite its high colonization efficiency. S7 A. veronii 501 was the only strain with inhibited growth and decreased survival in water over time, which may 502 have contributed to its inability to recover colonization capacity after loperamide treatment. In 503 the mix-reconventionalized fish, S7 A. veronii was the most abundant strain in the loperamide-504 treated zebrafish at T0, but significantly decreased at T1 and T5, consistent with its colonization 505 in the mono-reconventionalized larvae and the conventional zebrafish composition. Other 506 bacteria- or host-related factors induced by the presence of loperamide could explain reduced 507 S7 A. veronii abundance, such as reduced feeding, chemokinesis, or motility [22, 59, 60]. 508 Previous studies of gnotobiotic zebrafish colonization have demonstrated the strain-specific 509 importance of chemotaxis and host gut motility for intestinal colonization [61, 62], bacterial

510 motility and host cues with *A. veronii*. [60], and general induction of host immune responses or 511 locomotive behavior [63–65]. In a mix-reconventionalized community, bacteria-bacteria 512 interactions also contribute to changes in relative abundance, regardless of host factors. For 513 example, the ecological niche left by S7 *A. veronii* due to direct inhibition or decreased 514 intestinal peristalsis from loperamide treatment, could explain why S3 *P. nitroreducens* showed 515 a significant increase at T1 only in loperamide-treated samples.

516

517 Interestingly, loperamide did not increase bacterial load at the measured timepoints in our study. 518 Similar results were also obtained in loperamide-induced constipation model in rats [66]. This 519 may be due to colonization constraints imposed by loperamide toxicity, the larval fish size, or 520 nutrient limitations, since previous studies of gnotobiotic zebrafish have also not detected more 521 than 10^6 CFUs/larvae [22, 63, 64]. Our study is limited to bulk culturable CFUs per fish 522 associated with 10 bacterial strains at 3 timepoints. Future studies should investigate the 523 localization and quantification of transit time of fluorescently tagged bacteria to further 524 understand intestinal-specific changes upon loperamide treatment.

525

526 In all previous studies where loperamide-induced constipation has been considered to affect the 527 host microbiome, these changes have been attributed to decreased stool frequency and increased 528 colonic contractions by inhibition of intestinal water secretion and colonic peristalsis, which 529 extends the fecal evacuation time and delays the intestinal luminal transit rate [15, 67]. 530 However, our results demonstrated that the changes in microbiota composition and diversity 531 are also partially due to strain-specific bacterial inhibition or promotion by the loperamide 532 exposure. In addition to the zebrafish-associated strains studied here, loperamide exhibits 533 bactericidal activity against diverse host-associated microbes including mycobacterial strains 534 (e.g. Mycobacterium tuberculosis) and Staphylococcus aureus, but not Escherichia coli [27, 535 68]. These microbes are members of the human and vertebrate microbiome that may be directly 536 affected by loperamide treatment, resulting in unforeseen microbiota modulation [69].

537

Prior studies of loperamide-induced gastro-intestinal disorders determined that various treatments restore host health and improve the associated symptoms (i.e. constipation or gut transit time). For example, konjac oligo-glucomannan alleviates defecation infrequency and suppressed the growth of *Bacteroides* in mice [70], raffino-oligosaccharide improved gastrointestinal transit rate and reduced the serum levels of vasoactive intestinal peptide in mice [71], and probiotics improved constipation by altering metabolite, amino acid, inflammatory 544 cytokines, and/or neurotransmitter abundances in rats [20, 72, 73]. In all of these studies, the 545 effect of treatment and changes in host physiology were inferred to constipation or the relevant 546 model phenotype. However, all of these described effects may also be attributed to ancillary 547 microbiota modulations. The perturbation of host microbiomes is frequently described to cause 548 significant changes in host metabolite and peptide abundances, immune response, and 549 physiology and health [1, 74, 75]. Our results indicate that animal models using loperamide to 550 study bowel dysfunction and constipation cannot distinguish the effects of loperamide on host 551 function from the effects of microbiota modulation by loperamide.

552

553 Conclusions

In summary, our results demonstrate that loperamide induces significant changes in the microbiota, which may influence experimental outcomes especially if the host immune system or behavior are considered. As a common medication used to alleviate diarrhea and bowel disorders in humans, loperamide is also likely to produce under-studied antibiotic effects on intestinal microbiota. This emphasizes the need to better characterize relationships between host physiological changes, microbial community structure, and disease or dysbiosis states.

560 Acknowledgements

We are grateful to Jean-Pierre Levraud, Yuliaxis Ramayo and Erin Witkop for critical reading 561 562 of the manuscript, and Bianca Audrain for assistance with obtaining the animal ethical 563 authorization. This work was supported by grants from the French Government's 564 Investissement d'Avenir program, Laboratoire d'Excellence "Integrative Biology of Emerging 565 Infectious Diseases" (grant n°ANR-10-LABX-62-IBEID) and by the Fondation pour la 566 Recherche Médicale (grant DEQ20180339185). RJS was supported by a grant from the Philippe Foundation. Sequencing was performed by G M. Haustant, L. Lemée, Biomics 567 568 Platform, C2RT, Institut Pasteur, Paris, France, supported by France Génomique (ANR-10-569 INBS-09-09) and IBISA. The graphical abstract and Figure 1 were created with 570 BioRender.com.

571

572 Authors' Contributions

573 RJS, JMG, and DPP contributed conception and design of the study. RJS and DPP performed 574 the experiments. SB and ND performed the zebrafish imaging assays. RJS analyzed the data 575 and wrote the first draft of the manuscript. All authors contributed to manuscript revision, read 576 and approved the submitted version.

577

578 **Competing Interests**

- 579 The authors declare no competing interests.
- 580

581 Ethics Statement

All animal experiments described in the present study were conducted at the Institut Pasteur according to European Union guidelines for handling of laboratory animals (<u>http://ec.europa.eu/environment/chemicals/lab_animals/home_en.htm</u>) and authorized by the Institut Pasteur Animal Health and Care Committees under permit #dap220109.

586

587 Availability of Data and Material

588 The raw 16S rRNA gene amplicon sequences generated for this study can be found in the NCBI

589 Sequencing Read Archive in <u>BioProject no. PRJNA908751</u>. All other raw data, processed

- 590 sequencing files, QIIME2 artifacts, and scripts to reproduce the figures in the manuscript are
- available in the Zenodo repository, <u>https://doi.org/10.5281/zenodo.7415697</u> [48].

592 **References**

- 593 1. Hill JH, Round JL. Snapshot: Microbiota effects on host physiology. Cell. 2021;184:2796-594 2796.e1.
- Solveng N, Bansept F, Sieber M, Traulsen A, Schulenburg H. Evolution of Microbiota–Host
 Associations: The Microbe's Perspective. Trends in Microbiology. 2021;:1–9.
- 597 3. Libertucci J, Young VB. The role of the microbiota in infectious diseases. Nature 598 Microbiology. 2019;4:35–45.
- 4. Henry LP, Bruijning M, Forsberg SKG, Ayroles JF. The microbiome extends host evolutionary potential. Nature Communications. 2021;12:1–13.
- 5. Wilkins LGE, Leray M, O'Dea A, Yuen B, Peixoto R, Pereira TJ, et al. Host-associated
 microbiomes drive structure and function of marine ecosystems. PLOS Biology.
 2019;17:e3000533.
- 604 6. Stecher B, Maier L, Hardt WD. "Blooming" in the gut: How dysbiosis might contribute to 605 pathogen evolution. Nature Reviews Microbiology. 2013;11:277–84.
- 606 7. Hooks KB, O'Malley MA. Dysbiosis and its discontents. mBio. 2017;8.
- 8. Douglas AE. Simple animal models for microbiome research. Nat Rev Microbiol.2019;17:764–75.
- 609 9. Clavel T, Lagkouvardos I, Stecher B. From complex gut communities to minimal 610 microbiomes via cultivation. Current Opinion in Microbiology. 2017;38 June:148–55.
- 611 10. Mooser C, Gomez de Agüero M, Ganal-Vonarburg SC. Standardization in host-microbiota
 612 interaction studies: challenges, gnotobiology as a tool, and perspective. Current Opinion in
 613 Microbiology. 2018;44:50–60.
- 614 11. Stagaman K, Sharpton TJ, Guillemin K. Zebrafish microbiome studies make waves. Lab
 615 Animal. 2020;49:201–7.
- 616 12. Zhang M, Shan C, Tan F, Limbu SM, Chen L, Du ZY. Gnotobiotic models: Powerful tools
 617 for deeply understanding intestinal microbiota-host interactions in aquaculture. Aquaculture.
 618 2020;517:734800.
- 619 13. Pham LN, Kanther M, Semova I, Rawls JF. Methods for generating and colonizing
 620 gnotobiotic zebrafish. Nature Protocols. 2008;3:1862–75.
- 14. Milligan-Myhre K, Charette JR, Phennicie RT, Stephens WZ, Rawls JF, Guillemin K, et al.
 Study of Host-Microbe Interactions in Zebrafish. In: Methods in Cell Biology. Academic Press
 Inc.; 2011. p. 87–116.
- 624 15. Awouters F, Megens A, Verlinden M, Schuurkes J, Niemegeers C, Janssen PAJ.
 625 Loperamide. Digest Dis Sci. 1993;38:977–95.
- 626 16. Baldi F, Bianco MA, Nardone G, Pilotto A, Zamparo E. Focus on acute diarrhoeal disease.
 627 World Journal of Gastroenterology. 2009;15:3341–8.

- 628 17. Diemert DJ. Prevention and self-treatment of traveler's diarrhea. Clinical Microbiology
 629 Reviews. 2006;19:583–94.
- 630 18. Li STT, Grossman DC, Cummings P. Loperamide therapy for acute diarrhea in children:
 631 Systematic review and meta-analysis. PLoS Medicine. 2007;4:495–505.
- 632 19. Touw K, Wang Y, Leone V, Nadimpalli A, Nathaniel H, Gianrico F, et al. Drug-induced
- constipation alters gut microbiota stability leading to physiological changes in the host. The
 FASEB Journal. 2014;28 1 Supplement.
- 635 20. Inatomi T, Honma M. Effects of probiotics on loperamide-induced constipation in rats.
 636 Scientific Reports. 2021;11:1–9.
- 637 21. Shi Y, Zhang Y, Zhao F, Ruan H, Huang H, Luo L, et al. Acetylcholine serves as a
 638 derepressor in Loperamide-induced Opioid-Induced Bowel Dysfunction (OIBD) in zebrafish.
 639 Scientific Reports. 2014;4:1–12.
- 640 22. Lu Y, Zhang J, Yi H, Zhang Z, Zhang L. Screening of intestinal peristalsis-promoting
 641 probiotics based on a zebrafish model. Food and Function. 2019;10:2075–82.
- 642 23. Yang L, Wan Y, Li W, Liu C, Li H fang, Dong Z, et al. Targeting intestinal flora and its
 643 metabolism to explore the laxative effects of rhubarb. Applied Microbiology and
 644 Biotechnology. 2022;106:1615–31.
- 645 24. Touw K, Ringus DL, Hubert N, Wang Y, Leone VA, Nadimpalli A, et al. Mutual
 646 reinforcement of pathophysiological host-microbe interactions in intestinal stasis models.
 647 Physiological Reports. 2017;5.
- 648 25. Wang G, Yang S, Sun S, Si Q, Wang L, Zhang Q, et al. Lactobacillus rhamnosus Strains
 649 Relieve Loperamide-Induced Constipation via Different Pathways Independent of Short-Chain
 650 Fatty Acids. Frontiers in Cellular and Infection Microbiology. 2020;10 August:1–14.
- 651 26. Hwang N, Eom T, Gupta SK, Jeong SY, Jeong DY, Kim YS, et al. Genes and gut bacteria
 652 involved in luminal butyrate reduction caused by diet and loperamide. Genes. 2017;8:1–12.
- 653 27. Barrientos OM, Juárez E, Gonzalez Y, Castro-Villeda DA, Torres M, Guzmán-Beltrán S.
 654 Loperamide exerts a direct bactericidal effect against M. tuberculosis, M. bovis, M. terrae and
 655 M. smegmatis. Letters in Applied Microbiology. 2021;72:351–6.
- 656 28. Juárez E, Ruiz A, Cortez O, Sada E, Torres M. Antimicrobial and immunomodulatory
 657 activity induced by loperamide in mycobacterial infections. International
 658 Immunopharmacology. 2018;65 June:29–36.
- 659 29. Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, et al. Extensive impact
 660 of non-antibiotic drugs on human gut bacteria. Nature. 2018;555:623–8.
- 30. Rendueles O, Ferrières L, Frétaud M, Bégaud E, Herbomel P, Levraud JP, et al. A new
 zebrafish model of oro-intestinal pathogen colonization reveals a key role for adhesion in
 protection by probiotic bacteria. PLoS Pathogens. 2012;8:12.
- 664 31. Eren AM, Vineis JH, Morrison HG, Sogin ML. A Filtering Method to Generate High665 Quality Short Reads Using Illumina Paired-End Technology. PLoS ONE. 2013;8:e66643.

- 32. Huse SM, Mark Welch DB, Voorhis A, Shipunova A, Morrison HG, Eren AM, et al.
 VAMPS: A website for visualization and analysis of microbial population structures. BMC
 Bioinformatics. 2014;15:41.
- 669 33. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: High-670 resolution sample inference from Illumina amplicon data. Nature Methods. 2016;13:581–3.
- 671 34. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al.
- 672 QIIME allows analysis of high-throughput community sequencing data. Nature Methods.
- 673 2010;7:335–6.
- 35. Bokulich NA, Kaehler BD, Rideout JR, Dillon M, Bolyen E, Knight R, et al. Optimizing
 taxonomic classification of marker-gene amplicon sequences with QIIME 2's q2-featureclassifier plugin. Microbiome. 2018;6:90.
- 677 36. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al.
 678 Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2.
 679 Nature Biotechnology. 2019;37:852–7.
- 680 37. Dixon P. VEGAN, a package of R functions for community ecology. Journal of Vegetation
 681 Science. 2003;14:927–30.
- 38. McMurdie PJ, Holmes S. Phyloseq: An R Package for Reproducible Interactive Analysis
 and Graphics of Microbiome Census Data. PLoS ONE. 2013;8:e61217.
- 684 39. Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, et al. Welcome to 685 the Tidyverse. Journal of Open Source Software. 2019;4:1686.
- 686 40. Chao A, Jost L. Coverage-based rarefaction and extrapolation: Standardizing samples by
 687 completeness rather than size. Ecology. 2012;93:2533–47.
- 41. Mcardle BH, Anderson MJ. Fitting Multivariate Models to Community Data : A Comment
 on Distance-Based Redundancy Analysis Published by : Ecological Society of America Stable
 URL : http://www.jstor.org/stable/2680104. Ecology. 2010;82:290–7.
- 42. Warton DI, Wright ST, Wang Y. Distance-based multivariate analyses confound location
 and dispersion effects. Methods in Ecology and Evolution. 2012;3:89–101.
- 43. Law CW, Chen Y, Shi W, Smyth GK. Voom: Precision weights unlock linear modelanalysis tools for RNA-seq read counts. Genome Biology. 2014;15:1–17.
- 44. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential
 expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research.
 2015;43:e47.
- 698 45. Cao Y. microbiomeMarker: microbiome biomarker analysis. 2020.
- 699 46. Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32:2847–9.
- 47. Conway JR, Lex A, Gehlenborg N. UpSetR: An R package for the visualization of
 intersecting sets and their properties. Bioinformatics. 2017;33:2938–40.

48. Stevick R. Analyses for Anti-diarrheal drug loperamide induces microbial dysbiosis in
larval zebrafish via targeted bacterial inhibition. Zenodo. 2022.
https://doi.org/10.5281/zenodo.7415697.

- 49. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of imageanalysis. Nature Methods. 2012;9:671–5.
- 50. Parichy DM, Elizondo MR, Mills MG, Gordon TN, Engeszer RE. Normal table of
 postembryonic zebrafish development: Staging by externally visible anatomy of the living fish.
 Developmental Dynamics. 2009;238:2975–3015.
- 51. Hinz C, Gebhardt K, Hartmann AK, Sigman L, Gerlach G. Influence of Kinship and MHC
 Class II Genotype on Visual Traits in Zebrafish Larvae (Danio rerio). PLoS ONE. 2012;7.
- 713 52. Sales Cadena MR, Cadena PG, Watson MR, Sarmah S, Boehm SL, Marrs JA. Zebrafish
- 714 (Danio rerio) larvae show behavioral and embryonic development defects when exposed to
- 715 opioids at embryo stage. Neurotoxicology and Teratology. 2021;85 February.
- 53. Stressmann FA, Bernal-Bayard J, Perez-Pascual D, Audrain B, Rendueles O, Briolat V, et
- al. Mining zebrafish microbiota reveals key community-level resistance against fish pathogen
- 718 infection. ISME Journal. 2021;15:702–19.
- 719 54. Perez-Pascual D, Vendrell-Fernandez S, Audrain B, Bernal-Bayard J, Patiño-Navarrete R,
- Petit V, et al. Gnotobiotic rainbow trout (Oncorhynchus mykiss) model reveals endogenous
- bacteria that protect against Flavobacterium columnare infection. PLoS Pathogens. 2021;17:1–
 21.
- 723 55. Kassambara A. ggpubr: "ggplot2" Based Publication Ready Plots. 2020.
- 724 56. Pedersen TL. patchwork: The Composer of Plots. 2020.
- 725 57. Wilke CO. ggtext: Improved Text Rendering Support for "ggplot2." 2020.
- 58. Kashyap PC, Marcobal A, Ursell LK, Larauche M, Duboc H, Earle KA, et al. Complex
 interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice.
 Gastroenterology. 2013;144:967–77.
- 59. Lebov JF, Schlomann BH, Robinson CD, Bohannan BJM. Phenotypic parallelism during
 experimental adaptation of a free-living bacterium to the zebrafish gut. mBio. 2020;11:1–17.
- 60. Robinson CD, Sweeney EG, Ngo J, Remington SJ, Bohannan BJM, Robinson CD, et al.
 Host-emitted amino acid cues regulate bacterial chemokinesis to enhance colonization. Cell
 Host and Microbe. 2021;:1–14.
- 61. Stephens WZ, Wiles TJ, Martinez ES, Jemielita M, Burns AR, Parthasarathy R, et al.
 Identification of population bottlenecks and colonization factors during assembly of bacterial
 communities within the zebrafish intestine. mBio. 2015;6:1–11.
- 737 62. Wiles TJ, Jemielita M, Baker RP, Schlomann BH, Logan SL, Ganz J, et al. Host Gut
- Motility Promotes Competitive Exclusion within a Model Intestinal Microbiota. PLoS Biology.
 2016;14:1–24.

- 63. Wiles TJ, Schlomann BH, Wall ES, Betancourt R, Parthasarathy R, Guillemin K.
 Swimming motility of a gut bacterial symbiont promotes resistance to intestinal expulsion and
 enhances inflammation. PLoS Biology. 2020;18:e3000661.
- 64. Weitekamp CA, Kvasnicka A, Keely SP, Brinkman NE, Howey XM, Gaballah S, et al.
 Monoassociation with bacterial isolates reveals the role of colonization, community complexity
 and abundance on locomotor behavior in larval zebrafish. Animal Microbiome. 2021;3:12.
- 746 65. Tan F, Limbu SM, Qian Y, Qiao F, Du ZY, Zhang M. The Responses of Germ-Free
 747 Zebrafish (Danio rerio) to Varying Bacterial Concentrations, Colonization Time Points, and
 748 Exposure Duration. Frontiers in Microbiology. 2019;10:2156.
- 66. Kim J-E, Choi Y-J, Lee S-J, Gong J-E, Jin Y-J, Park S-H, et al. Laxative Effects of
 Phlorotannins Derived from Ecklonia cava on Loperamide-Induced Constipation in SD Rats.
 Molecules. 2021;26:7209.
- 67. Schiller LR, Santa Ana CA, Morawski SG, Fordtran JS. Mechanism of the Antidiarrheal
 Effect of Loperamide. Gastroenterology. 1984;86:1475–80.
- 68. Chai CLL, Teo SLM, Jameson FKM, Lee SSC, Likhitsup A, Chen C-L, et al. Loperamide-based compounds as additives for biofouling management. Scopus. 2014.
- 69. Huttenhower C, Human Microbiome Project Consortium. Structure, function and diversityof the healthy human microbiome. Nature. 2012;486:207–14.
- 758 70. Hayeeawaema F, Wichienchot S, Khuituan P. Amelioration of gut dysbiosis and
 759 gastrointestinal motility by konjac oligo-glucomannan on loperamide-induced constipation in
 760 mice. Nutrition. 2020;73:110715.
- 761 71. Liang Y, Wang Y, Wen P, Chen Y, Ouyang D, Wang D, et al. The Anti-Constipation Effects
 762 of Raffino-Oligosaccharide on Gut Function in Mice Using Neurotransmitter Analyses, 16S
 763 rRNA Sequencing and Targeted Screening. Molecules. 2022;27.
- 764 72. Eor JY, Tan PL, Lim SM, Choi DH, Yoon SM, Yang SY, et al. Laxative effect of probiotic
 765 chocolate on loperamide-induced constipation in rats. Food Research International.
 766 2019;116:1173–82.
- 767 73. Makizaki Y, Uemoto T, Yokota H, Yamamoto M, Tanaka Y, Ohno H. Improvement of
 768 loperamide-induced slow transit constipation by Bifidobacterium bifidum G9-1 is mediated by
 769 the correction of butyrate production and neurotransmitter profile due to improvement in
 770 dysbiosis. PLoS ONE. 2021;16 3 March:1–13.
- 771 74. Fontaine SS, Kohl KD. Optimal integration between host physiology and functions of the
 772 gut microbiome. Philosophical Transactions of the Royal Society B: Biological Sciences.
 773 2020;375:20190594.
- 774 75. Levy M, Blacher E, Elinav E. Microbiome, metabolites and host immunity. Current Opinion
 775 in Microbiology. 2017;35:8–15.
- 776